20,993 ingestions in 412 study participants: No serious adverse events related to the ingestible sensor or patch were reported in these clinical studies, Changes in gastric pH (from 1.6 to 7) or chloride or pepsin concentration did not impact ingestible sensor conductivity, Ingestible sensor is safe; tested for chemical, electrical, and mechanical safety and toxicology, Positive detection accuracy is 99.1% (95% confidence interval: 97.3% – 99.7%), BMI ranged from 16.0 to 56.8 kg/m2 in these studies, Overall accuracy was 97.6% (95% confidence interval: 96.7% – 98.3%), No adverse events occurred in relation to the sensor, Minor skin irritation (pruritis) in 23 subjects (28%), Moderate skin irritation (contact dermatitis) in 2 subjects (2%). The "smart pill" maker indicated in the filing that it has between $100 million and $500 million in estimated assets, and between $50 million and $100 million in estimated liabilities. With that backdrop, Novartis invested in Proteus in 2010, an agreement that allowed the drugmaker to license Proteus technology for organ transplantation, following a small study to track patients' compliance with their blood pressure drugs. A digital sensor the size of a grain of sand is housed in a pill.
But the treatment never gained material traction with patients, according to two people familiar with the matter, making it hard to keep top talent. Proteus Digital Health valuation is $1.6 b,. It's also not obvious who should be monitoring patients if they stop taking medications. Value greater if considering the data from the US Hypertension and Diabetes cluster-randomized controlled study, 288 participants took direct acting antivirals (co-encapsulated with the Proteus ingestible sensor pill) for 8-12 weeks, SVR was achieved in 99.1% of 218 participants who had HCV RNA assessed at ≥10 weeks post-treatment, Pill-taking adherence was 95.0% in the 218 participants, More than 80% of respondents strongly agreed that Proteus Discover® helped them feel motivated to achieve their treatment goals, 68% of study participants had a household income under $25k, 61.1% had psychiatric comorbidities, and 47% had active alcohol or substance abuse, Mean detection accuracy of 98.7% (range 94% to 100%) with digitized combination of rifampin and isoniazid, Demonstrated bioequivalence of co-encapsulated digital medicine with non-digitized form, Compared costs associated with WOT to DOT (3 or 7 days per week) for tuberculosis treatment, 7-day DOT costs were $3472 vs. $1273 for WOT, Personnel costs associated with DOT explain much of the difference, Reduction in costs allows providers to treat 1.4 to 2.7 times as many patients with WOT. Raising additional money also became a bigger challenge. Monday to Friday 6:00 AM – 4:00 PM Pacific. A Division of NBCUniversal. All Rights Reserved. Proteus Digital Health has spent two decades trying to develop "smart pills" that can be used to tell a smartphone app whether patients have taken their medications. The company has experienced a wave of high-level departures in the past few years, such as Chief Commercial Officer Molly O'Neill, who left in 2018. At Proteus, the furloughed employees were brought back to work in recent weeks after the company was able to land $5 million in emergency funding, according to people with knowledge of the matter.
84 Proteus Digital Health reviews. ". The Discover Portal allows physicians to quickly drill down into specific patient data points and allocate care team resources to those patients who need it most.
A free inside look at company reviews and salaries posted anonymously by employees. Patients can also set multiple medication-taking schedules and receive notifications. Sign up for free newsletters and get more CNBC delivered to your inbox. Proteus Digital Health, a once-hot health technology startup that had invented a digital pill, is planning to cut hundreds of jobs and close facilities in Redwood City and Hayward. A Division of NBCUniversal. We want to hear from you. Proteus Digital Health General Information Description. After-hours answering services available to report issues and schedule a call-back. Sign up for free newsletters and get more CNBC delivered to your inbox. But investors have noted that while the approach is promising, it has historically been a challenge to marry the digital and pharma sectors. Estimated $1020 – $1260 per patient per year of value for payers when Proteus is used by patients with comorbid hypertension, type 2 diabetes, and hypercholesterolemia. Medication non-adherence leads to uncontrolled health conditions, excess hospitalizations, emergency room visits and office visits, resulting in additional cost to the U.S. healthcare system of $528 billion annually.2,3, Non-adherence is multifactorial and must be addressed by understanding the underlying cause (e.g. side effects, lack of understanding of the disease, and dosing schedule). Sorry, your blog cannot share posts by email. With Proteus Discover 98% of patients with uncontrolled hypertension and diabetes who failed to achieve goal while on therapy with at least 2 anti-hypertensives and 1 diabetes medicine achieved their BP targets within 90 days. Spring Ridge Ventures owns almost all of its Series A preferred stock. The company's products include ingestible sensors, a small wearable sensor patch, an application on a mobile device and a digital portal for data analytics, enabling healthcare providers to more effectively manage risk and ensure that outcomes are reliably achieved leading to … Proteus captured 48% more medication ingestions than gold-standard, directly observed, therapy. Proteus Digital Health interview details: 41 interview questions and 40 interview reviews posted anonymously by Proteus Digital Health interview candidates. Proteus landed a deal earlier this year to provide digital medicines to Tennessee's Medicaid program for patients undergoing hepatitis C treatments, but … At one point, the "smart pill" maker was valued at $1.5 billion according to Forbes. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u, gna aliqua. Proteus has started focusing on other conditions outside of mental health. 2Anderson G. Chronic conditions: making the case for ongoing care. For general inquires regarding Proteus or our products: Proteus helped healthcare providors determine which patients needed medication titration versus those that needed adherence counseling. Proteus Discover is the world’s first Digital Medicine offering designed for health organizations searching for an efficient, patient-centric approach to measure, manage and improve the health of patient populations. The company’s technology was thought to be so promising that at one point, Proteus had achieved a valuation of $1.5 billion. A representative from Otsuka said that the company won't be putting out any official statement on its business partner's bankruptcy, but said that delivery of Abilify MyCite – a sensor-enabled version of Otsuka's schizophrenia drug that was developed as a result of the companies' collaboration – will not be affected. Abilify MyCite made waves when it received the FDA's green light back in late 2017, with some musing that the adherence technology could become a game changer for the pharmaceutical industry.
Patients don't always take their meds and don't necessarily know if they're up to date with them. The world has discovered Proteus Digital Health. Baltimore, MD: Johns Hopkins University; 2010. http://www.rwjf.org/content/dam/farm/reports/reports/2010/rwjf54583 Stat News reported that a deal with Otsuka was terminated in January of this year. Proteus Discover is comprised of ingestible sensors, a small wearable sensor patch, an application on a mobile device and a provider portal. All Access Digital offer for just 99 cents! All rights reserved. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. © 2020 MobiHealthNews is a publication of HIMSS Media.